CKW Financial Group Has $599,000 Position in Johnson & Johnson (NYSE:JNJ)

CKW Financial Group lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,141 shares of the company’s stock after selling 592 shares during the period. Johnson & Johnson accounts for 0.1% of CKW Financial Group’s portfolio, making the stock its 28th largest position. CKW Financial Group’s holdings in Johnson & Johnson were worth $599,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. McLean Asset Management Corp grew its stake in shares of Johnson & Johnson by 6.2% during the fourth quarter. McLean Asset Management Corp now owns 3,390 shares of the company’s stock worth $490,000 after purchasing an additional 198 shares during the period. waypoint wealth counsel grew its position in shares of Johnson & Johnson by 4.0% during the 4th quarter. waypoint wealth counsel now owns 5,092 shares of the company’s stock worth $736,000 after buying an additional 196 shares during the period. Union Bancaire Privee UBP SA bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $85,886,000. Apexium Financial LP boosted its stake in Johnson & Johnson by 108.1% during the 4th quarter. Apexium Financial LP now owns 21,679 shares of the company’s stock worth $3,135,000 after acquiring an additional 11,262 shares during the last quarter. Finally, Capital Asset Advisory Services LLC grew its holdings in Johnson & Johnson by 2.1% during the fourth quarter. Capital Asset Advisory Services LLC now owns 30,252 shares of the company’s stock valued at $4,362,000 after purchasing an additional 631 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $152.78 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a 50 day simple moving average of $147.73 and a 200 day simple moving average of $156.10. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market cap of $367.82 billion, a P/E ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the business posted $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.44.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.